Advanced search
Publication Cover
Current Opinion on Therapeutic Patents Volume 2, 1992 - Issue 4
Journal homepage
8
Views
0
CrossRef citations to date
0
Altmetric
Anti-Inflammatory, Anti-Allergic, Respiratory & GI Agents

Overview: Recent Developments in Anti-ulcer Agents

Kálmán Harsányi Chemical Works of Gedeon Richter Ltd, H-1475 Budapest POB 27 Hungary
&
István Szabadkai Chemical Works of Gedeon Richter Ltd, H-1475 Budapest POB 27 Hungary
Pages 385-399 | Published online: 02 Mar 2011

References to Primary Literature

  • Lauritsen K, Laursen LS, Rask-Madsen J Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part I). Clin. Pharmacokinet. Jul, 1990 19 1 11–31.
  • Isenberg JI Should safety concerns with available ulcer treatment influence drug selection?. J. Clin. Gastroenterol. 1990 12 Suppl 2 S48–S53.
  • Peterson WL Pathogenesis and therapy of peptic ulcer disease. J. Clin. Gastroenterol. 1990 12 Suppl 2 S1–S6.
  • Walt RP Prostaglandins and peptic ulcer therapy. Scand. J. Gastroenterol. Suppl. 1990 174 29–36.
  • Thomson AB Acid secretion and acid suppression in pathogenesis and healing of peptic ulcer disease. Hepatogastroenterology 1990 37 Suppl 1 18–28.
  • Haglund U Stress ulcers. Scand. J Gastroenterol. Suppl. (Norway) 1990 175 27–33.
  • McCarthy DM NSAID-induced gastrointestinal damage. A critical review of prophylaxis and therapy. J. Clin. Gastroenterol. 1990 12 Suppl 2 S13–S20.
  • Lamers CB Hormonal regulation of gastric acid in peptic ulcer disease. Scand. J. Gastroenterol. Suppl. 1988 146 5–10.
  • Sun HS Recent advances in the treatment of digestive diseases. J. Int. Med. Res. 1989 17 Suppl 1 2A–8A.
  • Hakanson R, Sundler F Proposed mechanism of induction of gastric carcinoids: The gastrin hypothesis. Eur. J. Clin. Invest. 1990 20 Suppl 1.
  • Wormsley KG Therapeutic achlorhydria and risk of gastric cancer. Gastroenterol. Jpn. 1989 24 5 585–596.
  • Lamers CB Is there a need for strong gastric acid inhibition in clinical practice?. Digestion 1989 44 Suppl 1 4–8.
  • Sainz-Samitier R, Gomollon-Garcia F Acid inhibition and long-term treatment of peptic ulcer disease. Methods Find. Exp. Clin. Pharmacol. 1989 11 Suppl 1 137–145.
  • Dammann HG, Dreyer M, Kangah R, Muller P, Simon B Optimal reduction of gastric acid secretion in the treatment of peptic ulceration. Drugs 1988 35 Suppl 3 106–113.
  • Wormsley KG Is chronic long-term inhibition of gastric secretion really dangerous?. Scand. J. Gastroenterol. Suppl. 1988 146 166–174.
  • Talley NJ, Ormand JE Is antibacterial therapy against Campylobacter pylori useful in the treatment of indigestion and chronic peptic ulceration?. Trends Pharmacol. Sci. 1989 10 1 36–40.
  • Czinn SJ, Speck WT Campylobacter pylori: A new pathogen. Adv. Pediatr. Infect. Dis. 1990 5 221–1990.
  • Wormsley KG Campilobacter pylori and ulcer disease - a causal connection?. Scand. J. Gastroenterol. Suppl. 1989 160 53–1989.
  • Wilson DE Gastroduodenal ulcers: Causes, diagnosis, prevention, and treatment. Compr. Ther. 1990 16 5 43–53.
  • Miller JP, Faragher EB The potential impact of Campylobacter pylori on the treatment of duodenal ulcer disease. Scand. J. Gastroenterol. Suppl. 1989 160 39–45.
  • Conference on Current Aspects of Ulcer Disease and Dyspepsia London, 12/13 December, 1991.
  • Miller P Clinical aspects of Helicobacter pylori.
  • Bell D The eradication of Helicobacter pylori: Current strategies.
  • Mills J The expanding role of the H2 antagonists.
  • Sachs G Omeprazole: Improving the treatment options mechanism by design.
  • Shield M.J The role of cytoprotective agents in ulcer disease.
  • Parsons M New developments in proton pump inhibitors.
  • Reynolds JC The clinical importance of drug interactions with anti-ulcer therapy. J. Clin. Gastroenterol. 1990 12 Suppl 2 S54–S63.
  • Lewis JH Long-term management of peptic ulcer disease. Compr. Ther. 1989 15 2 55–61.
  • Ponce J, Rodrigo JM Therapeutic failure and relapse in peptic ulcer. Methods Find. Exp. Clin. Pharmacol. 1989 11 Suppl 1 123–130.
  • Dent J, McCloy RF, Garner A, Matthews JB, Rune S, Blum AL Current and future drugs for acid-peptic disease: A plethora of opinions on possible mechanisms of action. DICP 1990 24 12 1226–1231.
  • Souney PF, Stoukides CA Pharmacoeconomic aspects and formulary considerations related to histamine2-receptor antagonists. DICP 1989 23 10 Suppl 29–S35.
  • Freston JW Overview of medical therapy of peptic ulcer disease. Gastroenterol. Clin. North Am. 1990 19 1 121–140.
  • Lam SK Prevention and management of relapse of peptic ulcer. Trop. Gastroenterol. (INDIA) 1990 11 4 173–185.
  • Langtry HD, Grant SM, Goa KL Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 1989 38 4 551–590.
  • Lampkin TA, Ouellet D, Hak LJ, Dukes GE Omeprazole: A novel antisecretory agent for the treatment of acid-peptic disorders. DICP 1990 24 4 393–402.
  • Riesz T private communication.
  • Robert A Cytoprotection by prostaglandins. Gastroenterology 1979 77 761–767.
  • Hogan DL, Isenberg JI Gastroduodenal bicarbonate production. Adv. Intern. Med. 1988 33 385–408.
  • Wilson DE, Quadros E, Rajapaksa T, Effects of misoprostol on gastric acid and mucus secretion in man. Dig. Dis. Sci. 1986 31 2 126s–129s.
  • Muller P, Fischer N, Dumman H.G, Simultaneous addition of 16,16, dimethyl PGE2 prevents aspirin and bile salt damage to human gastric mucosa. Gastroenterology 1981 19 373–376.
  • Lichtenberger LM, Graziani LA, Dial E, Role of surface active phospholipides in gastric cytoprotection. Science 1983 219 1327–1329.
  • Sato N, Kawano S, Futeuda M, Misoprostol-induced changes in gastric mucosal hemodynamics. Am. J. Med. 1987 83 1A 15–21.
  • McCarthy DM Nonsteroidal anti-inflammatory drug-induced ulcers: Management by traditional therapies. Gastroenterology 1989 96 Suppl 2 662–674.
  • Agrawal NM, Dajani EZ Treatment and prevention of nonsteroidal anti-inflammatory drug induced gastrointestinal mucosal injury. J. Clin. Pharmacol. Res. 1989 9 6 347–357.
  • Tytgat GN Future potential applicability of sucralfate in gastroenterology. Scand. J. Gastroenterol. Suppl. 1990 173 34–38.
  • Hollander D, Tarnawski A Citoprotective and therapeutic mechanisms of sucralfate. Scand. J. Gastroenterol Suppl. 1990 173 1–5.
  • Lam SK Implications of sucralfate-induced ulcer healing and relapse. Am. J. Med. 1989 86 6A 122–126.
  • Lam SK Antacids: The past, the present, and the future. Baillieres. Clin. Gastroenterol. 1988 2 3 641–54.
  • Drugs of Future 1990 640.
  • Drug Development Research 1989 17 185–197.
  • Drugs Exptl. Clin. Res. 1989 XV 2 83–89.
  • Pharmaprojects 1991 May A2B2.

References to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.